Objective: Glucagon-like peptide-1 (GLP-1) is a peptide hormone secreted by intestinal L-cells which stimulates glucose-dependent insulin secretion. GLP-1 is initially secreted as the active peptide GLP-17-36/7, but rapidly undergoes cleavage by dipeptidyl peptidase 4 (DPP4) to yield the inactive form, GLP-19-36/7. Despite a reduced affinity for the GLP-1 receptor, GLP-19-36/7 may have cardioprotective properties. There is currently no described immunoassay capable of specifically measuring GLP-19-36/7.
Design and methods: We generated a monoclonal antibody specific for the N-terminal neoepitope of GLP-19-36/7. After affinity maturation, we paired this capture antibody with an anti-total GLP-1 monoclonal detection antibody to create a sandwich ELISA specific for GLP-19-36/7.
Results: The sandwich ELISA was highly specific for GLP-19-36/7 and did not recognize GLP-17-36 or GLP-17-37. The ELISA exhibited a broad dynamic range and a lower limit of detection (LLOD) of 3.17ng/L. In healthy volunteers, concentrations of GLP-19-36/7 increased dramatically in the postprandial state compared to the fasted state and were markedly elevated at both 30 and 120-minute postprandial time points.
Conclusions: The optimization of an N-terminal-specific monoclonal antibody for GLP-19-36/7 enabled the development of a sensitive and specific sandwich ELISA assay capable of measuring physiological concentrations of GLP-19-36/7. This ELISA may have the potential to help expand our knowledge of GLP-1 biology.
Keywords: Diabetes; GLP-1(9–36/7); Glucagon; Incretin; Insulin; Peptide.
Copyright © 2016 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.